SEN. BINGAMAN CALLS FOR NEW FDA HEAD; OTHERS SAY LEADERSHIP NOT AT ISSUE
A change in top FDA leadership is required to correct the alleged problems at the agency, according to one Democratic senator. But observers of the FDA and the pharmaceutical industry say the current leadership is not at fault.
This article is viewable by subscribers only. To view this article, please select an option below.